Shanghai Pharmaceuticals Holding Co., Ltd. (Shanghai Pharma) has formally entered into the Partnership Agreement to participate in the establishment of the Shanghai Biomedical Phase II Fund. The agreement was signed on 24 July 2026, confirming the principal terms previously outlined in the company’s 18 July 2026 announcement regarding the connected transaction.

The update signals the Board’s approval to advance the investment initiative, which is expected to strengthen Shanghai Pharma’s strategic presence in the biomedical sector. All other details disclosed in the earlier announcement remain unchanged.